Epidemiology and Survival Factors of Amyotrophic Lateral Sclerosis (ALS) in a Large Chinese Cohort

Amyotrophic lateral sclerosis (ALS)—a progressive, fatal neurodegenerative disease that destroys the motor neurons controlling muscle movement—affects hundreds of thousands worldwide. Yet, until recently, little was known about how ALS presents, progresses, and impacts survival in Chinese populations. A 2021 study from Peking University Third Hospital aimed to change that, analyzing data from nearly 2,000 ALS patients to uncover critical patterns in epidemiology, clinical features, and prognosis.

What the Study Did

Researchers led by Ming Gao, Na Liu, and Xue-Mei Li (with contributions from Peking University Third Hospital, Weifang Medical University Affiliated Hospital, and Fuwai Central China Cardiovascular Hospital) conducted a clinic-based prospective cohort study from January 2005 to December 2015. They reviewed records from 1,809 ALS patients diagnosed using the internationally recognized El Escorial revised criteria—excluding other motor neuron diseases (e.g., progressive muscular atrophy) and neurodegenerative conditions (e.g., Parkinson’s disease) to ensure focus.

Data collected included demographics (age, gender, residency), clinical details (site of onset, diagnostic delay, functional status via the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised, or ALSFRS-R), and environmental factors (occupation, pesticide exposure). Survival time was defined as the interval from symptom onset to death, tracheostomy, or final follow-up. Statistical tools like Kaplan-Meier curves (for survival comparisons) and Cox proportional hazards models (for adjusting confounders) were used to analyze results.

Key Epidemiological Findings

The study revealed unique patterns in how ALS affects Chinese patients:

Incidence: The average annual crude incidence in Beijing was 0.38 cases per 100,000 people—lower than rates in Europe (1.5–2.5 per 100,000) and North America. Researchers note this may reflect underdiagnosis rather than a true lower risk.
Age of Onset: The mean age when symptoms began was 48.9 years—far younger than the 62–66 years reported in Europe and Japan. Younger onset may be linked to higher environmental pollution in less developed regions, though this needs further study.
Gender Ratio: Men were 1.87 times more likely to be diagnosed than women—consistent with global trends.
Familial vs. Sporadic: Only 5.7% of cases were familial ALS (inherited), matching the 5–10% global rate. Most cases (94.3%) were sporadic (no clear genetic link).

Clinical Features: How ALS Presents in China

Two critical clinical patterns emerged:

Site of Onset: A full 85% of patients had limb onset (symptoms starting in arms or legs), compared to 60–70% in Europe. Bulbar onset (symptoms starting in speech/swallowing muscles) affected just 15%—a stark contrast to Western cohorts, where bulbar onset is more common.
Diagnostic Delay: The average time from symptom onset to diagnosis was 25 months—more than double the 12-month delay seen in Europe and the U.S. This gap may reflect differences in healthcare access or awareness: slower progression in some Chinese patients could delay seeking care, or non-specialists may misdiagnose early symptoms.

Survival Factors: What Predicts Longer (or Shorter) Life with ALS

The study confirmed four independent predictors of survival—factors that directly influence how long patients live after diagnosis:

Age at Onset: Older patients had worse outcomes. Those over 70 were 3.4 times more likely to die or need tracheostomy than patients under 50.
Diagnostic Delay: Shorter time to diagnosis correlated with shorter survival. Patients diagnosed within a year of onset were 3.4 times more likely to progress rapidly—suggesting faster disease progression leads to earlier diagnosis.
ALSFRS-R Decline: The rate of functional decline (measured by monthly ALSFRS-R score drops) was a strong predictor. Patients losing ≥0.75 points per month were twice as likely to have poor outcomes as those with slower decline.
Body Mass Index (BMI): Higher BMI was linked to longer survival. Patients with a BMI over 25 (overweight) had a 64% lower risk of early death than those underweight (BMI <18.5). This aligns with global research: higher BMI may provide energy reserves to combat hypermetabolism (a common ALS feature).

How Chinese Data Compares to Global Trends

While some findings mirror global ALS research (e.g., gender ratio, familial rate), others are uniquely Chinese:

Younger Onset: The 48.9-year mean age is a standout difference—possibly tied to environmental exposures (e.g., pesticides, air pollution) more common in younger populations in developing regions.
Limb Onset Dominance: Why do most Chinese ALS patients start with limb symptoms? Researchers speculate genetic or environmental factors may protect bulbar motor neurons, but more studies are needed.
Longer Diagnostic Delay: Healthcare disparities—especially in rural areas—may explain why Chinese patients wait longer for a diagnosis. Improving specialist access could shorten this delay and improve care.

Limitations and Next Steps

The study has constraints: it excluded juvenile ALS and other motor neuron diseases, and it didn’t analyze cognitive status or tracheostomy’s impact on survival. Still, it’s a landmark for Chinese ALS research.

For clinicians, the findings highlight the need for:

Earlier screening in older patients (who progress faster).
Monitoring ALSFRS-R decline to predict prognosis.
Nutritional support to maintain BMI (a simple way to extend survival).

For researchers, the study underscores the importance of exploring environmental factors (e.g., pesticide exposure, home remodeling) in Chinese ALS cases.

Conclusion

This large cohort study fills a critical gap in ALS research, providing the first comprehensive look at how the disease affects Chinese patients. While survival factors (age, diagnostic delay, functional decline, BMI) align with global trends, the younger onset and limb-dominant presentation are uniquely Chinese. These insights will help clinicians tailor care, design clinical trials, and develop tools to predict progression—ultimately improving outcomes for the thousands of Chinese families affected by ALS.

The study was published in the Chinese Medical Journal in 2021.
doi.org/10.1097/CM9.0000000000001679

Was this helpful?

0 / 0